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September 2009706 Letters to the Editorreport if the total aortic cross-clamping time is significantly associ-
ated with spinal cord injury in a multivariate regression analysis
model, independently of the combination of other protective
strategies.
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Reply
The publication of Biglioli et al1 comprises patients with
descending thoracic aneurysms and the very short clamping times
indicate the limited extent of the aneurysms in a substantial num-
ber of patients. Aortic arch arteries at the proximal site or visceral
arteries at the distal site were not involved in the aneurysm. The
majority of these aneurysms would currently be treated by means
of endovascular techniques.
The pathology of patients in our publication is entirely differ-
ent and, therefore, not comparable. The aortic pathology included
the aortic arch, descending aorta, and/or the abdominal aorta,
affecting supra-aortic, visceral, and renal arteries. Total aortic
clamp times in these extensive repairs exceed many hours and
would not be tolerated without extracorporeal circulation. There-
fore, we did not consider aortic clamp times as an important
parameter.
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Regarding “What a vascular surgeon should know
and do about atherosclerotic risk factors”
Liapis et al provide an excellent guide for the management of
the various conventional, conditional and emerging vascular risk
factors.1
A risk factor that may deserve more attention is hypertriglyc-
eridemia. Currently, hypertriglyceridemia is considered as a condi-tional risk factor.1 According to the AHA/ACC Guidelines,2 as
well as the recommendations of the authors,1 lowering triglyceride
levels 1.7 mmol/l (150 mg/dl) is a secondary target, whereas
lowering low-density lipoprotein cholesterol (LDL-C) levels2.6
mmol/l (100 mg/dl) is a primary target. However, if triglycer-
ides are 500 mg/dl, the treatment of LDL-C to goal becomes a
secondary target;2 triglyceride-lowering therapy should be initiated
immediately to prevent the development of acute pancreatitis.2
The importance of aiming at normal triglyceride levels to
prevent cardiovascular disease could already be extrapolated from a
study published more than three decades ago.3 This study evalu-
ated the presence of coronary artery disease and peripheral arterial
disease (PAD) in 280 patients with different types of primary
hyperlipoproteinemia. It was demonstrated that the prevalence of
PAD was much higher in patients with hypertriglyceridemia (21%
in Type IIb; 20% in Type V) than in subjects with hypercholester-
olemia alone (9% in Type IIa).3
In a nested case-control study, plasma samples were collected
at baseline from a prospective cohort of 14,916 initially healthy
individuals aged 40 to 84 years.4 During an average follow-up
period of nine years, 140 subjects developed PAD. Although the
total cholesterol/high-density lipoprotein cholesterol ratio was the
strongest predictor for the development of PAD (relative risk
[RR], 3.4; 95% confidence interval [CI], 1.7-7.0; P .001), high
triglyceride levels at baseline were an independent risk factor and
almost equally strong predictor (RR, 2.9; 95% CI, 1.4-5.8; P 
.001).4
Similarly, the Atherosclerosis Risk in Communities (ARIC)
Study assessed the relation of traditional and non-traditional risk
factors with the risk of PAD in 1,651 participants with diabetes,
but not PAD, at baseline.5 After a mean follow-up of 10.3 years,
the risk of developing PAD was increased 1.75-fold (95% CI:
1.18-2.60) for the highest versus the lowest quartile of triglycer-
ides.5 Surprisingly, no evidence was found of any association
between the development of PAD with other blood lipids or
hypertension.5
Hypercholesterolemia is indeed the strongest predictor of
cardiovascular disease and should thus comprise a primary thera-
peutic target.1,2,4 Nevertheless, hypertriglyceridemia should not
be viewed as a secondary therapeutic goal under all circumstances
(eg, when triglycerides500 mg/dl).2 Hypertriglyceridemia is an
important vascular risk factor, the management of which should
not be neglected. Given the association between hypertriglyceri-
demia, atherosclerosis, and cardiovascular risk,6 future guidelines
may need to consider hypertriglyceridemia as a conventional and
not a conditional risk factor.1
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Thank you for your referral to our paper. Classifying athero-
sclerotic risk factors as conventional, predisposing, conditional,
and emerging represents current evidence on the relation, direct or
indirect, of the risk factor to atherosclerosis.
Regarding triglycerides, though clearly associatedwith cardiovas-
cular disease (CVD), whether they are causally related to atheroscle-
rosis and the exactmechanisms bywhich triglyceride-rich lipoproteins
exert their noxious effect on the vascular wall are matters of debate.
Primarily, it is still unclear whether it is the number of triglyceride-rich
lipoprotein particles or triglyceride-rich lipoprotein cholesterol or the
associated small dense low-density lipoprotein (LDL) and low
high-density lipoprotein(HDL) which contribute most to athero-
sclerosis. Secondarily, abnormal triglyceride concentrations often
accompany conditions, such as diabetes mellitus type 2 and the
metabolic syndrome, directly associated with increased CVD risk.1
When, however, solitary severe hypertriglyceridemia exists (eg, in
patients with familial lipoprotein lipase (LPL) or apolipoprotein
C-II deficiency, without diabetes or other CVD risk factors),
premature atherosclerosis is not usually seen.2
It should also be noted that in neither the Helsinki Heart
Study3 (4081 middle-aged men with elevated non-HDL-C ran-
domly received gemfibrozil 600 mg twice a day or placebo) nor
Veterans Affairs High Density Lipoprotein Cholesterol Interven-
tion Trial (VA-HIT)4,5 (2531 men with low HDL-C levels and
coronary heart disease (CHD) randomly received gemfibrozil
1200 mg/d or placebo) could any benefit be attributed to the
lowering of triglycerides, despite that both found a substantial reduc-
tion in CHD risk in association with gemfibrozil. In the Helsinki
Heart Study, benefit was associated with reduction of LDL-C levels
and an increase in HDL-C levels, whereas in VA-HIT, benefit was
associated with an increase in HDL-C levels and alteration of HDL
particles, as well as a decrease in inflammatory markers.
American College of Cardiology/AmericanHeart Association
(AHA/ACC) Guidelines suggest that if triglycerides are 500
mg/dl, the treatment of LDL-C to goal becomes a secondary
target.6 In this setting only, it is sensible to prioritize triglyceride-
lowering therapy, but not to primary prevent atherosclerosis, but
mainly to reduce the risk of pancreatitis. The recommendation is of
level C evidence.
Hypertriglyceridemia has not yet been established as a direct
causative factor of atherogenesis. Current evidence cannot support
classification of hypertriglyceridemia among conventional risk fac-
tors. We agree, however, that, it is an important vascular risk factor
associated to CVD and should not be neglected in the overall
management of the vascular patient.
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Regarding “Silent embolic infarcts on computed
tomography brain scans and risk of ipsilateral
hemispheric events in patients with asymptomatic
internal carotid artery stenosis”
In their elegant study, Dr Kakkos et al. found an increased risk
of ipsilateral symptomatic ischemic events in patients who had an
asymptomatic but hemodynamically significant internal carotid
artery stenosis and a previous ipsilateral silent embolic infarct.1
This is of great interest because, if it indicates a causal link between
the carotid artery stenosis and both the silent infarct and the
subsequent symptomatic event, then there is room for preventive
interventions like carotid endarterectomy or carotid artery stent-
ing. However, the study findings could also be explained by the
fact that silent brain infarcts, including ipsilateral ones, are non-
specific risk factors for subsequent symptomatic ischemic events,
including ipsilateral ones.2 A few more analyses could help inter-
preting the results before an intervention study.
First, if the carotid artery stenosis causes at least some of the
ipsilateral silent embolic infarcts, we expect finding more embolic
infarcts on the ipsilateral side on baseline computed tomography
(CT) scan. However, Table II of the article shows that more
infarcts were actually seen in the contralateral hemisphere. As
noted by the authors, patients with previous symptomatic con-
tralateral ischemic events were not excluded from the study and
could explain this surprise finding. How then, are baseline infarcts
distributed between the ipsi- and contralateral brain hemispheres
when patients with previous contralateral symptoms are excluded
from the analysis?
Second, if the relation between ipsilateral silent embolic in-
farcts and subsequent ipsilateral strokes is non-specific, we expect
that contralateral silent embolic infarcts will predict subsequent
ipsilateral strokes as well and, conversely, that ipsilateral silent em-
bolic infarct will predict subsequent contralateral strokes. What
then, is the ipsilateral stroke-free rate in patients with and without
a previous contralateral silent embolic infarct, and the contralateral
stroke-free rate in patients with and without a previous ipsilateral
silent embolic infarct?
Third, the authors provide stroke free survival rates in
patients with a previous ipsilateral embolic infarct and 60% to
99% stenosis or 60% to 79% stenosis. In both groups, there was
a striking difference compared with patients without previous
